Respiratory Syncytial Viral (RSV) Infections
Conditions
Keywords
Respiratory syncytial virus, Case control, monoclonal antibody, nirsevimab
Brief summary
Respiratory syncytial virus (RSV) is a leading cause of hospitalizations for acute lower respiratory tract infection (LRTI) in infants. In Australia approximately 1.5% of infants are hospitalized due to RSV, 80% of whom are born full-term and are otherwise healthy. Two randomized trials have used a seasonal implementation strategy to show nirsevimab, a long-acting monoclonal antibody, has sustained efficacy against RSV LRTI hospitalizations in the first 150-180 days after administration. Nirsevimab has been approved in many countries for the prevention of RSV-LRTI in neonates and infants. However, the protection offered by nirsevimab beyond 180 days remains unknown. Queensland is a large Australian state spanning the tropical and sub-tropical climate zones, where RSV circulates year-round. The Queensland government publicly funded nirsevimab for all infants at birth from 15 April 2024. The aim of this study is to estimate the duration of effectiveness of nirsevimab against RSV-related hospitalizations. A case-control study will be conducted using routinely collected linked data. Cases will be children born in Queensland from 15 April 2024 to 14 April 2025 who are hospitalised with an RSV-related condition prior to 14 April 2026. Controls will be drawn from the set of infants who are admitted to the same hospital in a 5:1 ratio, and matched on age and sex using the Queensland Perinatal Data Collection. Nirsevimab receipt will be extracted from hospital's electronic medical records and linked to hospitalization data by the Queensland Health Data Linkage Unit. Duration of protection against RSV-related hospitalisation due to nirsevimab will be assessed using multivariable logistic regression model accounting for matching and adjusting for confounding variables. This case-control study will determine the level and duration of protection offered by nirsevimab in a region with year-round RSV circulation and inform future prevention strategies. Interim analysis is expected to be available at the time of the conference, allowing for early dissemination of this first evidence about nirsevimab duration of protection beyond 180 days. Funding: From Sanofi and AstraZeneca through a collaboration grant.
Interventions
None listed
Sponsors
Griffith University
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 1 Years
Healthy volunteers
No
Inclusion criteria
Any infant born between 15 April 2024 and 30 April 2025 and hospitalized for any reason between 15 April 2024 and 30 April 2026.
Exclusion criteria
Infants who admitted to hospitals with an elective admission. ((i.e. admissions that are planned ahead of time, such as scheduled surgeries or other pre-arranged medical procedures).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The duration of effectiveness of nirsevimab against RSV-related hospitalizations. | From mid April 2024 to mid April 2026 |
Secondary
| Measure | Time frame |
|---|---|
| Estimate the quantities of the laboratory confirmed RSV hospitalization length of stay and paediatric intensive care unit admission that were prevented by a 12-month year-round nirsevimab immunization program in Queensland infants. | From mid April 2024 to mid April 2026 |
| Estimate the quantities of all cause acute respiratory hospitalization and PICU admissions that were prevented by nirsevimab immunization program in Queensland infants | From mid April 2024 to mid April 2026 |
| Estimate the quantities of all death from RSV-related illness that were prevented by a 12-month year-round nirsevimab immunization program in Queensland infants | From mid April 2024 to mid April 2026 |
| Evaluate the impact of nirsevimab on the cost of hospital services in Queensland, Australia | From mid April 2024 to mid April 2026 |
Countries
Australia
Outcome results
None listed